Roche Holding AG (RHHVF) AI Stock Analysis
Roche Holding AG
(Other OTC:RHHVF)
No summary available
Roche Holding AG (RHHVF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $334.60B
- Dividend Yield
- 2.55%
- Average Volume (3M)
- 3,751
- Price to Earnings (P/E)
- 26.3
- Beta (1Y)
- 0.36
- Revenue Growth
- 8.13%
- EPS Growth
- 42.70%
- Country
- US
- Employees
- 103,249
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Roche Holding AG Business Overview & Revenue Model
Company Description
Roche Holding AG is a prominent global entity primarily active in the pharmaceutical and diagnostics industries. Its extensive operations encompass numerous countries, including key markets such as Switzerland, Germany, the United States, Austria, th...
Roche Holding AG Earnings Call Summary
The call conveyed strong operational and financial momentum (core operating profit +10%, margin expansion, robust cash flow) combined with substantial pipeline and regulatory momentum (5 FDA priority reviews, 80% Phase III success YTD, multiple product launches/CE marks, and strategic diagnostics M&A). Headwinds were acknowledged and specific: China diagnostics pricing reform, weaker respiratory season, currency translation effects, net debt increase from dividends/timing, competitive pressures (biosimilars) and some impairments. Overall, the positive operational and pipeline developments materially outweigh the challenges, and management maintained confident guidance (mid-single-digit sales growth, high-single-digit core EPS growth) while flagging manageable near-term risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Roche stuck to its 2026 guidance: mid‑single‑digit sales growth (group H1 at 6%), high‑single‑digit core EPS growth (core EPS +9% in H1) and a further dividend increase in CHF; management reiterated an expected LOE headwind of roughly CHF 600m for 2026. H1 showed core operating profit +10% (core operating margin +1.7pp), pharma +6% and diagnostics +3% (diagnostics +6% ex‑China; China -15%), with a flu‑season impact of >CHF200m (~1%). Cash metrics were strong: operating free cash flow +21% (+2% in CHF), free cash flow +58% (+26% in CHF), while net debt rose CHF 5.9bn (gross debt ~CHF31.8bn). Diagnostics reaffirmed a 2026 ambition to keep margins broadly stable (~14.4% FY25 level) while targeting mid‑single‑digit sales growth and mid‑ to high‑single‑digit growth in 2027; management also flagged currency headwinds (~‑4 to ‑6 ppts on FY sales/OP/EPS) and a core tax rate of 17.5% in H1, expected to be around 20% for the full year, and said other revenue is expected to rise from ~3% to ~5% of sales by the end of the decade.
Roche Holding AG Peers Comparison
Overall Rating
CH:ALC73Outperform
CH:NOVN71Outperform
CH:TECN68Neutral
CH:NWRN45Neutral
CH:MOLN44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CH:ALC | 73Outperform | CHF 29.53B | 54.96 | 2.91% | 0.47% | -0.87% | -44.90% |
| CH:NOVN | 71Outperform | CHF 244.89B | 31.19 | ― | 2.77% | -4.48% | -33.14% |
| CH:TECN | 68Neutral | CHF 3.17B | -26.96 | -10.25% | 1.21% | -3.98% | -284.91% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CH:NWRN | 45Neutral | CHF 191.15M | -6.68 | 258.11% | ― | -82.88% | -212.48% |
| CH:MOLN | 44Neutral | CHF 116.68M | -2.13 | -79.25% | ― | -100.00% | 24.46% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RHHVF | Roche Holding | 485.68 | 184.63 | 61.33% | |
| CH:MOLN | Molecular Partners | 2.89 | -0.34 | -10.66% | |
| CH:NOVN | Novartis | 133.78 | 37.22 | 38.54% | |
| CH:ALC | Alcon | 59.10 | 0.43 | 0.73% | |
| CH:NWRN | Newron Pharmaceuticals SpA | 9.00 | -5.10 | -36.17% | |
| CH:TECN | Tecan Group AG | 247.00 | 108.93 | 78.89% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.